SCM
CCCC icon

Suvretta Capital Management’s C4 Therapeutics CCCC Stock Holding History

Suvretta Capital Management’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-143,482
Closed -$4.75M – 111
2020
Q4 		$4.75M Buy
+143,482
New +$4.16M 0.07% 79

Other funds holding CCCC

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Suvretta Capital Management's CCCC Position: Q1 2021 in Review

Suvretta Capital Management sold out of C4 Therapeutics (CCCC) in Q1 2021, closing a stake of 143,482 shares — an estimated $4.75M sold.

Suvretta Capital Management first reported a position in CCCC in Q4 2020 and held it in 1 quarter. The position peaked at $4.75M in Q4 2020. 83 funds tracked by Wall St. Rank hold CCCC as of Q1 2021.

  • Suvretta Capital Management reported no remaining C4 Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Suvretta Capital Management sold 143,482 C4 Therapeutics shares in Q1 2021, an estimated $4.75M.
  • Suvretta Capital Management first reported a position in C4 Therapeutics in Q4 2020 and held it in 1 quarter.
  • Suvretta Capital Management's C4 Therapeutics position peaked at $4.75M in Q4 2020.
  • 83 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2021.

Based on Suvretta Capital Management's 13F filing for Q1 2021, filed 17 May 2021.